The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy

被引：29

作者：

Choi J. ^{[1
]}

Kim H.J. ^{[1
]}

Jeong Y.H. ^{[1
]}

Lee J.-H. ^{[1
]}

Cho A. ^{[1
]}

Yun M. ^{[1
]}

Lee J.D. ^{[1
]}

Kim Y.B. ^{[2
]}

Kim Y.T. ^{[3
]}

Kang W.J. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, 120-752, 134 Shinchon-dong, Seodaemoon-gu

[2] Department of Radiation Oncology, Yonsei University College of Medicine, Seoul

[3] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul

来源：

Nuclear Medicine and Molecular Imaging | 2014年 / 48卷 / 2期

关键词：

CCRT; Cervical cancer; PET/CT; Treatment response;

D O I：

10.1007/s13139-013-0248-y

中图分类号：

学科分类号：

摘要：

Purpose: To determine whether persisting cervical fluorodeoxyglucose (FDG) uptake after concurrent chemoradiotherapy (CCRT) for cervical cancer can reflect residual malignancy. Methods: F-FDG PET/CT was performed before and after CCRT in 136 patients with cervical cancer. The maximum and mean standardized uptake values (SUVmax and SUVmean) were recorded from PET/CT scans performed pre- and post-treatment. SUVs were correlated with treatment response after CCRT. Final treatment response was determined by MRI and further follow-up PET/CT. One hundred four of 136 patients underwent pelvic MRI, and 32 of 136 patients underwent further follow-up PET/CT. Patients were classified into two categories: patients with residual tumor or patients without residual tumor (complete responder). Pre- and post-treatment serum squamous cell carcinoma antigen (SCC) levels were also recorded for comparison. The optimal cutoff value of SUVmax for predicting residual cervical tumor was determined using receiver-operating characteristic (ROC) analysis. Results: Of 136 patients, 124 showed complete response on further follow-up studies and 12 were confirmed to have residual tumor. The post-treatment SUVmax and pre-/post-treatment SUVmean of complete responders were significantly lower than those of patients with residual tumor: 2.5 ± 0.8 and 7.2 ± 4.2/1.9 ± 0.7 for complete responders and 5.7 ± 2.6 and 12.8 ± 6.9/3.7 ± 0.7 for patients with residual tumor (p < 0.05). The pre-treatment SUVmax and pre-/post-treatment serum SCC levels of the complete responders tended to be lower than those of patients with residual tumor, but this did not have statistical significance. Using ROC analysis, an optimal cutoff SUVmax of 4.0 on the post-treatment PET/CT yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 92 %, 94 %, 61 %, and 99 %, respectively (p < 0.001). Conclusions: Persistent cervical FDG uptake in18F-FDG PET/CT after CCRT for cervical cancer may be caused by residual tumor or post-therapy inflammation. A higher cutoff SUVmax than conventional criteria for cervical cancer in post-CCRT PET/CT might help to detect residual tumor. © 2013 Korean Society of Nuclear Medicine.

引用

页码：130 / 136

页数：6

共 27 条

[1]

Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J., Cancer statistics, CA Cancer J Clin, 59, pp. 225-249, (2009)

[2]

Pecorelli S., Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium, Int J Gynecol Obstet, 105, pp. 103-104, (2009)

[3]

Patel C.N., Nazir S.A., Khan Z., Gleeson F.V., Bradley K.M., <sup>18</sup> F-FDG PET/CT of cervical carcinoma, AJR Am J Roentgenol, 196, 5, pp. 1225-1233, (2011)

[4]

Monk B.J., Tewari K.S., Koh W.J., Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions, J Clin Oncol, 25, pp. 2952-2965, (2007)

[5]

Eifel P.J., Winter K., Morris M., Levenback C., Grigsby P.W., Cooper J., Et al., Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01, J Clin Oncol, 22, 5, pp. 872-880, (2004)

[6]

Sommers G.M., Grigsby P.W., Perez C.A., Camel H.M., Kao M.S., Galakatos A.E., Et al., Outcome of recurrent cervical carcinoma following definitive irradiation, Gynecol Oncol, 35, 2, pp. 150-155, (1989)

[7]

Grigsby P.W., Siegel B.A., Dehdashti F., Lymph node staging by positron emission tomography in patients with carcinoma of the cervix, J Clin Oncol, 19, 17, pp. 3745-3749, (2001)

[8]

Jacobs A.J., Faris C., Perez C.A., Kao M.S., Galakatos A., Camel H.M., Short-term persistence of carcinoma of the uterine cervix after radiation: an indicator of longterm prognosis, Cancer, 57, 5, pp. 944-950, (1986)

[9]

Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, pp. 228-247, (2009)

[10]

Lee M., Lee Y., Hwang K.H., Choe W., Park C.Y., Usefulness of F-18 FDG PET/CT in Assessment of Recurrence of Cervical Cancer After Treatment, Nucl Med Mol Imaging, 45, 2, pp. 111-116, (2011)

← 1 2 3 →